Find Suzetrigine manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 2649467-58-1, 2-pyridinecarboxamide, 4-[[[(2r,3s,4s,5r)-3-(3,4-difluoro-2-methoxyphenyl)tetrahydro-4,5-dimethyl-5-(trifluoromethyl)-2-furanyl]carbonyl]amino]-, Suzetrigine [inn], Log73m21h5, Schembl23462160, Gtpl12630
Molecular Formula
C21H20F5N3O4
Molecular Weight
473.4  g/mol
InChI Key
XSQUJFKRXZMOKA-PAFIKIDNSA-N
FDA UNII
LOG73M21H5

Suzetrigine
1 2D Structure

Suzetrigine

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
4-[[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)oxolane-2-carbonyl]amino]pyridine-2-carboxamide
2.1.2 InChI
InChI=1S/C21H20F5N3O4/c1-9-14(11-4-5-12(22)15(23)16(11)32-3)17(33-20(9,2)21(24,25)26)19(31)29-10-6-7-28-13(8-10)18(27)30/h4-9,14,17H,1-3H3,(H2,27,30)(H,28,29,31)/t9-,14-,17+,20+/m0/s1
2.1.3 InChI Key
XSQUJFKRXZMOKA-PAFIKIDNSA-N
2.1.4 Canonical SMILES
CC1C(C(OC1(C)C(F)(F)F)C(=O)NC2=CC(=NC=C2)C(=O)N)C3=C(C(=C(C=C3)F)F)OC
2.1.5 Isomeric SMILES
C[C@H]1[C@H]([C@@H](O[C@@]1(C)C(F)(F)F)C(=O)NC2=CC(=NC=C2)C(=O)N)C3=C(C(=C(C=C3)F)F)OC
2.2 Other Identifiers
2.2.1 UNII
LOG73M21H5
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. 2649467-58-1

2. 2-pyridinecarboxamide, 4-[[[(2r,3s,4s,5r)-3-(3,4-difluoro-2-methoxyphenyl)tetrahydro-4,5-dimethyl-5-(trifluoromethyl)-2-furanyl]carbonyl]amino]-

3. Suzetrigine [inn]

4. Log73m21h5

5. Schembl23462160

6. Gtpl12630

7. Vx548

8. Ex-a7354

9. Vx-548

10. Compound 7 [wo2021113627a1]

11. Hy-148800

12. Cs-0641183

13. 4-[(2r,3s,4s,5r)-3-(3,4-difluoro-2-methoxyphenyl)-4,5- Dimethyl-5-(trifluoromethyl)oxolane-2- Carboxamido]pyridine-2-carboxamide

14. 4-[[(2r, 3s, 4s, 5r)-3-(3, 4-difluoro-2-methoxyphenyl)-4, 5-dimethyl-5-(trifluoromethyl)oxolane-2-carbonyl]amino]pyridine-2-carboxamide

15. 4-[[(2r,3s,4s,5r)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)oxolane-2-carbonyl]amino]pyridine-2-carboxamide

16. 4-[[[(2r,3s,4s,5r)-3-(3,4-difluoro-2-methoxyphenyl)tetrahydro-4,5-dimethyl-5-(trifluoromethyl)-2-furanyl]carbonyl]amino]-2-pyridinecarboxamide

2.4 Create Date
2021-08-21
3 Chemical and Physical Properties
Molecular Weight 473.4 g/mol
Molecular Formula C21H20F5N3O4
XLogP33
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count10
Rotatable Bond Count5
Exact Mass g/mol
Monoisotopic Mass g/mol
Topological Polar Surface Area104
Heavy Atom Count33
Formal Charge0
Complexity741
Isotope Atom Count0
Defined Atom Stereocenter Count4
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

API SUPPLIERS

read-more
read-more

01

HRV Global Life Sciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
HRV Global Life Sciences

02

Mankind Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDelivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Company Banner

03

Honour Lab

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

Honour Lab

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

04

Hefei Home Sunshine Pharmaceutical...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

05

Excenen PharmaTech

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

Excenen PharmaTech

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

06

FandaChem

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

FandaChem

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

07

Olon S.p.A

Italy

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

Olon S.p.A

Italy

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

08

Hovione

Portugal

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

Hovione

Portugal

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

SUZETRIGINE

NDC Package Code : 50909-1910

Start Marketing Date : 2025-01-30

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (0.25kg/kg)

Marketing Category : DRUG FOR FURTHER PROCESSING

blank

02

Olon S.p.A.

Italy
AACR Annual meeting
Not Confirmed
arrow

Olon S.p.A.

Italy
arrow
AACR Annual meeting
Not Confirmed

SUZETRIGINE

NDC Package Code : 17337-0437

Start Marketing Date : 2024-10-16

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.

Flag India
Digital Content Digital Content

Suzetrigine

About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...

HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It offers services such as sourcing, manufacturing & supply, helping partners enter new markets worldwide. Its strong partnerships with major players in the pharma and food additive industries help HRV Global effectively promote projects and products. HRV Global represents over 30 large Indian drugmakers, primarily targeting Europe, the US & the Middle East markets. Headquartered in India, HRV Global has offices in the US, Switzerland, Dubai, Lithuania & Turkey.
HRV Global Life Sciences

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDelivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.

Flag India
Digital Content Digital Content

Suzetrigine

About the Company : Mankind Pharma, came into existence in 1986. In 1991, the company was formed into a legal corporation. However, it actively started working as a fully integrated pharmaceutical com...

Mankind Pharma, came into existence in 1986. In 1991, the company was formed into a legal corporation. However, it actively started working as a fully integrated pharmaceutical company in 1995. Today, we have 11,000 employees and are heading towards a turnover of INR 50000 million. Our vast network includes 50 C&F agents and 7500+ stockists. We provide a wide range of products – Antibiotic, Antifungal, NSAIDs, Gastrointestinal, Anthelmintic, Cardiovascular, Dermal, Erectile Dysfunction, and several other categories – across the nation.
Company Banner

03

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Suzetrigine

About the Company : Founded by chemists with years of working experiences in famous CRO companies in China, Excenen Pharmatech experienced in organic chemistry expecially in medicinal chemistry resear...

Founded by chemists with years of working experiences in famous CRO companies in China, Excenen Pharmatech experienced in organic chemistry expecially in medicinal chemistry research/discovery fields. Excenen PharmaTech is dedicated to serve the pharmaceutical, scientific research and development industries for 10 years. During the past 10 years we supplied building blocks, small molecules, inhitbitors to world's leading companies like Janssen (Johnson&Johnson), Gilead, Abbvie..., Universities like Duke University, University of Chicago, University of Barcelona, University of Pécs etc.
blank

04

FandaChem

China
AACR Annual meeting
Not Confirmed
arrow

FandaChem

China
arrow
AACR Annual meeting
Not Confirmed

Suzetrigine

About the Company : FandaChem, headquartered in Hangzhou, China, is a reputable supplier and exporter of chemicals with a focus on delivering high-quality products. Our expertise lies in exporting a w...

FandaChem, headquartered in Hangzhou, China, is a reputable supplier and exporter of chemicals with a focus on delivering high-quality products. Our expertise lies in exporting a wide range of superior chemicals, specializing in areas such as agrochemicals, flavors, fragrances, pharmaceuticals, intermediates, paints, resins, plastics, surfactants, polymers, cosmetics, and more. Dedicated to being your dependable partner in China, FandaChem is devoted to offering top-notch products, competitive prices, and excellent service to meet the needs of our customers.
blank

05

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Suzetrigine

About the Company : Hefei Home Sunshine Pharmaceutical Technology Co., Ltd.is a high-tech enterprise, which is an integration of R & D, producing and custom synthesis. The products quality is assured ...

Hefei Home Sunshine Pharmaceutical Technology Co., Ltd.is a high-tech enterprise, which is an integration of R & D, producing and custom synthesis. The products quality is assured because of our continuously-optimizing management and technology innovation, complete QA system, advanced testing methods and equipments. We have won the trust of a wide range of customers/partners in the industry. Our Products include active pharmaceutical ingredients (API), pharmaceutical and agrochemical intermediates and chiral compounds.
blank

06

Honour Lab

India
AACR Annual meeting
Not Confirmed
arrow

Honour Lab

India
arrow
AACR Annual meeting
Not Confirmed

Suzetrigine

About the Company : Honour is a leading global Contract Development and Manufacturing Organization (CDMO) as well as a manufacturer of specialty chemicals and ingredients, operating six facilities tha...

Honour is a leading global Contract Development and Manufacturing Organization (CDMO) as well as a manufacturer of specialty chemicals and ingredients, operating six facilities that adhere to international standards of safety and quality. Through our offerings, Honour Synthesis and Honour Specialty, we are committed to fostering partnerships and exploring new possibilities. Our team of over 2,000 professionals delivers exceptional service to our pharmaceutical and biotechnology partners by providing practical solutions.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Journavx (suzetrigine) is an investigational oral, selective NaV1.8 inhibitor, which is currently being evaluated for the treatment of adult patients with moderate-to-severe acute pain.


Lead Product(s): Suzetrigine

Therapeutic Area: Neurology Brand Name: Journavx

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 30, 2025

blank

01

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : Journavx (suzetrigine) is an investigational oral, selective NaV1.8 inhibitor, which is currently being evaluated for the treatment of adult patients with moderate-to-severe acute pain.

Product Name : Journavx

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

January 30, 2025

blank

Details:

VX-548 (suzetrigine) is an investigational oral, selective NaV1.8 inhibitor, which is currently being evaluated for the treatment of patients with painful lumbosacral radiculopathy.


Lead Product(s): Suzetrigine

Therapeutic Area: Neurology Brand Name: VX-548

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 19, 2024

blank

02

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : VX-548 (suzetrigine) is an investigational oral, selective NaV1.8 inhibitor, which is currently being evaluated for the treatment of patients with painful lumbosacral radiculopathy.

Product Name : VX-548

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

December 19, 2024

blank

Details:

VX-548 (suzetrigine) is an investigational oral, selective NaV1.8 inhibitor, which is currently being evaluated for the treatment of patients with moderate-to-severe acute pain.


Lead Product(s): Suzetrigine

Therapeutic Area: Neurology Brand Name: VX-548

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 30, 2024

blank

03

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : VX-548 (suzetrigine) is an investigational oral, selective NaV1.8 inhibitor, which is currently being evaluated for the treatment of patients with moderate-to-severe acute pain.

Product Name : VX-548

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

July 30, 2024

blank

Details:

VX-548 (suzetrigine) is an investigational oral, selective NaV1.8 inhibitor, which is currently being evaluated for the treatment of patients with moderate-to-severe acute pain.


Lead Product(s): Suzetrigine

Therapeutic Area: Neurology Brand Name: VX-548

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 18, 2024

blank

04

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : VX-548 (suzetrigine) is an investigational oral, selective NaV1.8 inhibitor, which is currently being evaluated for the treatment of patients with moderate-to-severe acute pain.

Product Name : VX-548

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

April 18, 2024

blank

Details:

VX-548 (suzetrigine) is a selective NaV1.8 inhibitor, which is being evaluated in phase 3 clinical trials for the treatment of moderate-to-severe acute pain.


Lead Product(s): Suzetrigine

Therapeutic Area: Neurology Brand Name: VX-548

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 30, 2024

blank

05

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : VX-548 (suzetrigine) is a selective NaV1.8 inhibitor, which is being evaluated in phase 3 clinical trials for the treatment of moderate-to-severe acute pain.

Product Name : VX-548

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

January 30, 2024

blank

Details:

VX-548 is an investigational oral, selective NaV1.8 inhibitor that is highly selective for NaV1.8. It is under clinical development for the treatment of painful diabetic peripheral neuropathy.


Lead Product(s): Suzetrigine

Therapeutic Area: Neurology Brand Name: VX-548

Study Phase: Phase IIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 13, 2023

blank

06

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : VX-548 is an investigational oral, selective NaV1.8 inhibitor that is highly selective for NaV1.8. It is under clinical development for the treatment of painful diabetic peripheral neuropathy.

Product Name : VX-548

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

December 13, 2023

blank

Details:

VX-548 is an oral, selective NaV1.8 inhibitor that is highly selective for NaV1.8 relative to other NaV channels. NaV1.8 is a voltage-gated sodium channel that plays a critical role in pain signaling in the peripheral nervous system.


Lead Product(s): Suzetrigine

Therapeutic Area: Neurology Brand Name: VX-548

Study Phase: Phase IIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 22, 2022

blank

07

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : VX-548 is an oral, selective NaV1.8 inhibitor that is highly selective for NaV1.8 relative to other NaV channels. NaV1.8 is a voltage-gated sodium channel that plays a critical role in pain signaling in the peripheral nervous system.

Product Name : VX-548

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

July 22, 2022

blank

Details:

VX-548 was generally well tolerated in both studies. Most adverse events (AEs) were mild to moderate and there were no serious adverse events (SAEs) related to VX-548. Fewer patients discontinued treatment in the mid- and high-dose VX-548 arms than in the placebo group.


Lead Product(s): Suzetrigine

Therapeutic Area: Neurology Brand Name: VX-548

Study Phase: Phase IIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 31, 2022

blank

08

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : VX-548 was generally well tolerated in both studies. Most adverse events (AEs) were mild to moderate and there were no serious adverse events (SAEs) related to VX-548. Fewer patients discontinued treatment in the mid- and high-dose VX-548 arms than in th...

Product Name : VX-548

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

March 31, 2022

blank

Details:

The Phase 2 studies are randomized, double-blind, placebo-controlled trials that will evaluate multiple doses of VX-548 in patients with acute pain following bunionectomy surgery or abdominoplasty surgery.


Lead Product(s): Suzetrigine

Therapeutic Area: Neurology Brand Name: VX-548

Study Phase: Phase IIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 19, 2021

blank

09

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : The Phase 2 studies are randomized, double-blind, placebo-controlled trials that will evaluate multiple doses of VX-548 in patients with acute pain following bunionectomy surgery or abdominoplasty surgery.

Product Name : VX-548

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

July 19, 2021

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

SUZETRIGINE

Brand Name : JOURNAVX

Dosage Form : TABLET;ORAL

Dosage Strength : 50MG

Packaging :

Approval Date : 2025-01-30

Application Number : 219209

Regulatory Info : RX

Registration Country : USA

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

SUZETRIGINE

Brand Name : JOURNAVX

Dosage Form : TABLET;ORAL

Dosage Strength : 50MG

Approval Date : 2025-01-30

Application Number : 219209

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

STOCK RECAP #PipelineProspector

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Market Place

Do you need sourcing support? Ask us

APIs

read-more
read-more
PharmaCompass
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

arrow
AACR Annual meeting
Not Confirmed
arrow
AACR Annual meeting
Not Confirmed

SUZETRIGINE

US Patent Number : 11834441

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 219209

Patent Use Code : U-4125

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2040-12-04

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty